Maravai closes sale of Protein Detection segment; amends Pfizer/BioNTech supply pact

MARAVAI LIFESCIENCES HOLDINGS, INC.

Closed sale of Vector Laboratories (Protein Detection) to Voyager Group/Thompson Street on Sept 2, 2021.
Disposition not considered a significant business; Vector CEO Lisa Sellers leaves Maravai.
Amendment to TriLink supply agreement with Pfizer and BioNTech shifts invoicing to shipment-based from milestone-based.
Amendment effective June 6, 2021; redacted pricing/billing terms included.
Deal amendments clarify payments for facility relocation and exclude certain payables from purchase price adjustments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.